Author of the publication

Please choose a person to relate this publication to

To differ between persons with the same name, the academic degree and the title of an important publication will be displayed. You can also use the button next to the name to display some publications already assigned to the person.

 

Other publications of authors with the same name

Single-chain Fv immunoliposomes for the targeting of fibroblast activation protein-expressing tumor stromal cells, , , and . Journal of Drug Targeting, 15 (6): 399--406 (2007)Targeted cancer immunotherapy: Mimicking physiological trans-presentation of IL-15. OncoImmunology, 1 (7): 1213--1214 (October 2012)An Antibody Fusion Protein for Cancer Immunotherapy Mimicking IL-15 \textlessi\textgreatertrans\textless/i\textgreater -Presentation at the Tumor Site, , , , and . Molecular Cancer Therapeutics, 11 (6): 1279--1288 (June 2012)IL-15-based trifunctional antibody-fusion proteins with costimulatory TNF-superfamily ligands in the single-chain format for cancer immunotherapy, , , , and . Molecular Cancer Therapeutics, (April 2019)Humanization of a mouse monoclonal antibody directed against a cell surface-exposed epitope of membrane-associated heat shock protein 70 (Hsp70), , , and . Molecular Biotechnology, 46 (3): 265--278 (2010)Advancing targeted co-stimulation with antibody-fusion proteins by introducing TNF superfamily members in a single-chain format, , , , , , and . OncoImmunology, 5 (11): e1238540 (November 2016)Combination of a bispecific antibody and costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy, , , , , and . Journal of Immunotherapy, 35 (5): 418--429 (June 2012)N-glycosylation as novel strategy to improve pharmacokinetic properties of bispecific single-chain diabodies, , , , , and . Journal of Biological Chemistry, 283 (12): 7804--7812 (2008)Antibody fusions with immunomodulatory proteins for cancer therapy. Pharmacology and Therapeutics, (October 2015)Tumor-targeted costimulation with antibody-fusion proteins improves bispecific antibody-mediated immune response in presence of immunosuppressive factors, , , and . OncoImmunology, 6 (12): e1361594 (December 2017)